LYFE Capital

LYFE Capital is a prominent Transpacific healthcare investment firm with a substantial asset under management (AUM) of approximately US$2 billion across multiple funds. Headquartered in Singapore, with additional offices in Shanghai, Hong Kong, and San Francisco, the firm strategically positions itself to capitalize on innovative and high-growth opportunities within the global healthcare sector. Their investment philosophy centers on identifying companies with strong potential for market disruption and significant patient impact, primarily focusing on the dynamic markets of the United States and China.

The firm's investment strategy is broad yet specialized, encompassing various segments of the healthcare value chain. LYFE Capital primarily targets growth equity, late-stage venture, and private equity opportunities, indicating a preference for more mature companies that have demonstrated product-market fit and are poised for significant scaling. Their portfolio spans critical areas such as biopharmaceuticals, medical devices, diagnostics, and healthcare services. This diversified approach allows them to mitigate risk while maximizing exposure to different growth drivers within the healthcare ecosystem, leveraging their deep industry expertise and extensive network.

Given their substantial AUM and focus on growth and late-stage investments, LYFE Capital typically deploys significant capital into its portfolio companies. While specific figures can vary based on the opportunity and stage, the firm's initial cheque sizes generally range from US$15 million to US$75 million. They often act as lead or co-lead investors in substantial funding rounds, as evidenced by their participation in multi-hundred-million-dollar rounds for companies like Everest Medicines and Ascentage Pharma. This strategic capital deployment is complemented by active involvement, offering portfolio companies operational guidance and access to their transpacific network to facilitate expansion and market penetration.